Crimson Publishers Publish With Us Reprints e-Books Video articles


Innovation in Tissue Engineering & Regenerative Medicine

Transplantation of Autologous Bone Marrow- Derived Stromal Cells in Type 2 Diabetes: A Pilot Study

Submission: December 04, 2019; Published: December 11, 2019

DOI: 10.31031/ITERM.2019.01.000517

ISSN: 2578-0336
Volume1 Issue4


Type 2 Diabetes is a debilitating metabolic disorder which is also the seventh leading cause of death worldwide. Current therapeutic regimes to date have failed to achieve significant long-term glycemic control even with intensive insulin therapy as revealed by deregulated Hb1Ac and C-peptides levels. In the current study, we have evaluated the effect of regenerative cellular therapy for functional recovery from Diabetic pathophysiology. 10 patients with a median age of 51 years were selected for the study and subjected to bone marrow isolation. These samples were processed under sterile conditions for the enrichment of mononuclear cells (BM MNCs) from bone marrow. After strict quality control and characterization of cells, 2 x 106 cells/kg of BM MNCs were infused back into the patient through the anterior pancreaticoduodenal artery. We performed an evaluation of clinical parameters like Body Mass Index, Fasting Plasma Glucose, Fasting Plasma Insulin, HbA1c and C-peptide levels, and followed up the patients for 12 months. Our study showed a reduction in insulin dependency by ≥ 50%.

Keywords: Type 2 diabetes; Pilot study; Bone marrow; BM MNCs; Autologous; Regenerative medicine

Get access to the full text of this article